The Conundrum of Rash in Management of EGFR Inhibitors
Presented by:
ArcMesa Educators
Lecturer
Roy S. Herbst, MD, PhD, Mario Lacouture, MD, Roman Perez-Soler, MD and Sandy Kurtin, RN, MS, AOCNŽ, NP
Approximate duration:
1 hr.
Summary points:
This audiovisual presentation reviews the dual role of the rash associated with growth factor receptor inhibitor treatment of cancer as a side effect and as clinical surrogate marker for response and/or survival, appropriate timing of early treatment to manage these adverse skin reactions, and recommended dose titration of various components of chemotherapeutic combinations to achieve best patient outcome.
Accreditation:
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ArcMesa Educators designates this educational activity for a maximum of 1 AMA PRA Category 1 credit.
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. Course UPN #200-000-06-023-H01.
Expiration date: October 9, 2007.
The Conundrum of Rash in Management of EGFR Inhibitors
